Livre Blanc
Accelerating Patient Access to Precision Oncology in Asia-Pacific
Feb 05, 2021
Download

The APAC region holds a diverse Health Technology Assessment (HTA) and pricing and reimbursement landscape. Current HTA approaches and economic evaluation methods may not fully capture the value of precision oncology, leading to delayed access to these innovative technologies. In collaboration with Roche, IQVIA developed a framework to characterize the market access ecosystem and state of adoption of precision oncology in APAC. Comprehensive genomic profiling and tumor-agnostic therapies were used as prime examples of precision oncology innovations. This paper reviews the varied HTA and pricing and reimbursement landscape in APAC, as well as discusses the challenges, opportunities and recommendations for sustainable access to precision oncology in the region.

 

Authors

  • Sirinthip Petcharapiruch, MSc, Principal, Real World Solutions, IQVIA, Asia Pacific
  • Junice Ng, PhD, Consultant, Real World Solutions, IQVIA, Asia Pacific
  • Eemin tan, PhD, Associate Consultant, Real World Solutions, IQVIA, Asia Pacific
Contact Us